Murray, Michael G. and Kuhn, Richard J. and Arita, Mineo and Kawamura, Noriyuki and Nomoto, Akio and Wimmer, Eckard (1988) Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proceedings of the National Academy of Sciences of the United States of America, 85 (9). pp. 3203-3207. ISSN 0027-8424. http://resolver.caltech.edu/CaltechAUTHORS:MURpnas88
See Usage Policy.
Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:MURpnas88
Poliovirus exists as three stable serotypes (PV-1, PV-2, and PV-3). These viruses display three antigenic sites each, designated N-AgI, N-AgII, and N-AgIII. When mice are immunized with poliovirus, N-AgI is the major neutralization antigenic site for PV-3, whereas N-AgII and N-AgIII are immunodominant over N-AgI for PV-1. To study the relationship between structure and antigenicity, a hybrid virus was constructed in which N-AgI of PV-1 was replaced by N-AgI of PV-3. PV-3- and PV-1-specific antisera, including those elicited by PV-3 in primates, neutralized the hybrid virus. Injection of the hybrid virus into rabbits or into primates resulted in the production of antisera that neutralized both PV-1 and PV-3. The data show that sequence replacement at N-AgI of poliovirus is compatible with viral proliferation, an observation useful for the development of multivalent picornavirus vaccines.
|Additional Information:||© 1988 by the National Academy of Sciences. Communicated by Michael G. Rossmann, January 22, 1988 (received for review October 29, 1987). We thank Dr. Michael G. Rossmann for his encouraging discussions. We are indebted to Dr. Emilio A. Emini for providing synthetic oligonucleotides, Drs. Olen Kew, Morag Ferguson, Philip Minor, Klaus Wiegers, and Rudolf Dernick for neutralizing monoclonal antibodies and Dr. John J. Dunn for providing us with RNA polymerase. We are grateful to Jonathan Bradley for useful suggestions; Christopher Helmke and Atsuko Kameda for photography, artwork, and technical assistance; and Lynn Zawacki for preparation of the manuscript. This work was supported in part by Public Health Service Grants AI 15122 and CA 28146 to E.W., by a grant from the Ministry of Education, Science and Culture of Japan to A.N., and by a grant from the Ministry of Health and Welfare to M.A. An account of this work has been presented in part (by M.G.M., R.J.K., and E.W.) at the Seventh International Congress of Virology, Aug. 9-14, 1987, Edmonton, AB, Canada, p. 137 (abstr.). The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.|
|Subject Keywords:||polio neutralizing antigenicity sites; divalent polio vaccine|
|Usage Policy:||No commercial reproduction, distribution, display or performance rights in this work are provided.|
|Deposited By:||Tony Diaz|
|Deposited On:||31 Oct 2007|
|Last Modified:||14 Nov 2014 19:20|
Repository Staff Only: item control page